First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

BACKGROUND: Children with HIV will be on antiretroviral therapy (ART) longer than adults, and therefore the durability of first-line ART and timing of switch to second-line are key questions. We assess the long-term outcome of protease inhibitor and non-nucleoside reverse transcriptase inhibitor (NN...

Full description

Bibliographic Details
Main Authors: Babiker, A, Castro nee Green, H, Compagnucci, A, Fiscus, S, Giaquinto, C, Gibb, D, Harper, L, Harrison, L, Hughes, M, McKinney, R, Melvin, A, Mofenson, L, Saidi, Y, Smith, M, Tudor-Williams, G, Walker, A
Format: Journal article
Language:English
Published: 2011

Similar Items